EGFR and gastric adenocarcinoma: The therapeutic backbone of metastatic STAD remains molecularly targeted therapies, which include HER2-targeting agents, anti-angiogenic agents, and epidermal growth factor receptor (EGFR) inhibitors (Alsina et al., 2019).